Molecular and immunophenotypic predictors of response to azacitidine (aza) as frontline therapy for acute myeloid leukemia (AML).

被引：0
|
作者：
Zimmerman, Michael Keith Alister
Grunwald, Michael Richard
Symanowski, James Thomas
Gerber, Jonathan Michael
机构：
[1] Levine Canc Inst, Charlotte, NC USA
[2] Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Questions Regarding Frontline Therapy of Acute Myeloid Leukemia
    Kantarjian, Hagop
    O'Brien, Susan
    CANCER, 2010, 116 (21) : 4896 - 4901
  • [32] Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients.
    Gardin, C.
    Itzykson, R.
    Thepot, S.
    Recher, C.
    Marfaing, A.
    Beyne-Rauzy, O.
    Boehrer, S.
    Dreyfus, F.
    Fenaux, P.
    Dombret, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN ELDERLY PATIENTS (≥75 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Buckstein, R.
    Santini, V.
    Doehner, H.
    Stone, R. M.
    Minden, M. D.
    Kuo, C. Y.
    Ben-Yehuda, D.
    Bargay, J.
    Songer, S.
    Weaver, J.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2017, 55 : S67 - S68
  • [34] ASSOCIATION OF MIR29 RNA WITH RESPONSE AND SURVIVAL IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR CONVENTIONAL CARE REGIMENS (CCR)
    MacBeth, K. J.
    Tang, L.
    Seymour, J. F.
    Stone, R. M.
    Minden, M. D.
    Lucy, L. M.
    Beach, C.
    Doehner, H.
    HAEMATOLOGICA, 2015, 100 : 317 - 317
  • [35] GLOBAL SURVIVAL (GS) ANALYSIS IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITHOUT FULL RESPONSE TO TREATMENT: AZACITIDINE VS CONVENTIONAL THERAPY (CT). SUB-ANALYSIS STUDY OF AZA-AML-001
    Falantes, J.
    Doehner, H.
    Dombret, H.
    Songer, S.
    Lucy Lela, M.
    Beach, C. L.
    Schuh, A.
    HAEMATOLOGICA, 2015, 100 : 18 - 19
  • [36] WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
    Stevens, Brett M.
    Winters, Amanda
    Abbasi, Taher
    Singh, Neeraj Kumar
    Ullal, Yashaswini S.
    Kumari, Ilu
    Tyagi, Anuj
    Alam, Aftab
    Lunkad, Neelesh
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    Vali, Shireen
    Pollyea, Daniel A.
    BLOOD, 2018, 132
  • [37] ASSESSMENT OF INFECTION EVENTS IN AZACITIDINE (AZA) TREATMENT FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML). A SINGLE CENTRE EXPERIENCE.
    Romero, P.
    Borras, J. B.
    Serra, F.
    Nigorra, M.
    Del Campo, R.
    Cladera, A.
    Vazquez, I.
    Mascaro, M.
    Gonzalez, E.
    Guerra, J. M.
    Gomez, D.
    Bargay, J.
    HAEMATOLOGICA, 2014, 99 : 196 - 196
  • [38] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [39] Interest of the association azacitidine–lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype
    E Scherman
    S Malak
    C Perot
    N C Gorin
    M T Rubio
    F Isnard
    Leukemia, 2012, 26 : 822 - 824
  • [40] Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
    Taenaka, Ryutaro
    Obara, Teppei
    Kohno, Kentaro
    Aoki, Kenichi
    Ogawa, Ryosuke
    INTERNAL MEDICINE, 2023, 62 (05) : 689 - 695
12345